BioCentury
ARTICLE | Clinical News

MEDI-565: Phase I started

January 24, 2011 8:00 AM UTC

AstraZeneca's MedImmune LLC subsidiary began a dose-escalation, single-arm, open-label, U.S. Phase I trial to evaluate MEDI-565 in patients with advanced gastrointestinal cancer. Once the maximum tol...